174 related articles for article (PubMed ID: 12180480)
21. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
22. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
Prescrire Int; 2013 Feb; 22(135):48-51. PubMed ID: 23444510
[TBL] [Abstract][Full Text] [Related]
23. [Flutamide-induced late cutaneous pseudoporphyria].
Mantoux F; Bahadoran P; Perrin C; Bermon C; Lacour JP; Ortonne JP
Ann Dermatol Venereol; 1999 Feb; 126(2):150-2. PubMed ID: 10352831
[TBL] [Abstract][Full Text] [Related]
24. Suspected cross-hepatotoxicity of flutamide and cyproterone acetate.
Miquel M; Soler A; Vaqué A; Ojanguren I; Costa J; Planas R
Liver Int; 2007 Oct; 27(8):1144-7. PubMed ID: 17845544
[TBL] [Abstract][Full Text] [Related]
25. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
[TBL] [Abstract][Full Text] [Related]
26. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
Bennett CL; Matchar D; McCrory D; McLeod DG; Crawford ED; Hillner BE
Cancer; 1996 May; 77(9):1854-61. PubMed ID: 8646685
[TBL] [Abstract][Full Text] [Related]
27. [Clinical efficacy of treatment with low-dose flutamide in maximum androgen blockade therapy].
Shimizu K; Kiyohara H; Nakayama J; Fujii T; Hosomi M
Hinyokika Kiyo; 2001 Apr; 47(4):251-5. PubMed ID: 11411099
[TBL] [Abstract][Full Text] [Related]
28. Flutamide-induced liver failure.
Møller S; Iversen P; Franzmann MB
J Hepatol; 1990 May; 10(3):346-9. PubMed ID: 2365984
[TBL] [Abstract][Full Text] [Related]
29. Maximal androgen blockade (MAB) for the treatment of prostate cancer.
Kirby RS
Br J Clin Pract; 1996; 50(5):287. PubMed ID: 8794610
[No Abstract] [Full Text] [Related]
30. Flutamide photosensitivity--residual vitiliginous lesions.
Vilaplana J; Romaguera C; Azón A; Lecha M
Contact Dermatitis; 1998 Feb; 38(2):68-70. PubMed ID: 9506217
[TBL] [Abstract][Full Text] [Related]
31. Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer.
Ozono S; Yamaguchi A; Mochizuki H; Kawakami T; Fujimoto K; Otani T; Yoshida K; Ichinei M; Yamashita T; Hirao Y
Prostate Cancer Prostatic Dis; 2002; 5(2):128-31. PubMed ID: 12497002
[TBL] [Abstract][Full Text] [Related]
32. Flutamide-induced acute hepatitis in advanced prostate cancer patients.
Kraus I; Vitezic D; Oguic R
Int J Clin Pharmacol Ther; 2001 Sep; 39(9):395-9. PubMed ID: 11563686
[TBL] [Abstract][Full Text] [Related]
33. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
Eastham JA; Sartor O
J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
[No Abstract] [Full Text] [Related]
34. [Flutamide-induced hepatic disorder and serum concentrations of flutamide and its metabolites in patients with prostate cancer].
Nakagawa Y; Koyama M; Matsumoto M
Hinyokika Kiyo; 1999 Dec; 45(12):821-6. PubMed ID: 10659414
[TBL] [Abstract][Full Text] [Related]
35. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
St-Arnaud R; Lachance R; Dupont A; Labrie F
Clin Invest Med; 1986 Nov; 9(4):215-21. PubMed ID: 2433088
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
37. Male breast adenocarcinoma in a prostate cancer patient following prolonged anti-androgen monotherapy.
Karamanakos P; Mitsiades CS; Lembessis P; Kontos M; Trafalis D; Koutsilieris M
Anticancer Res; 2004; 24(2C):1077-81. PubMed ID: 15154626
[TBL] [Abstract][Full Text] [Related]
38. [Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].
Takada T; Ishizuya Y; Okada T; Ueda T; Inoue H; Hara T
Hinyokika Kiyo; 2011 Jun; 57(6):291-5. PubMed ID: 21795830
[TBL] [Abstract][Full Text] [Related]
39. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Cherrier MM; Rose AL; Higano C
J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
[TBL] [Abstract][Full Text] [Related]
40. [The antiandrogen withdrawal syndrome: decrease in prostate specific antigen serum levels after withdrawal of antiandrogens].
Hornák M; Bárdos A; Goncalves F
Rozhl Chir; 1997 Sep; 76(9):435-7. PubMed ID: 9471771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
